Actively Recruiting
Phase 2 Study of Azacitidine and Venetoclax to Treat Adults With Acute Myeloid Leukemia and Measurable Residual Disease Before Stem Cell Transplant
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-24
30
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying whether a combination of azacitidine and venetoclax can effectively reduce or eliminate measurable residual disease MRD in adults with acute myeloid leukemia AML who have already received standard chemotherapy and plan to undergo an allogeneic hematopoietic stem cell transplant HSCT. This transplant involves receiving healthy stem cells from a donor to replace the patients immune system and help prevent the disease from returning. Participants receive treatment cycles lasting 28 days. Azacitidine is given at a dose of 75 mgm2 daily for the first 7 days, usually through intravenous IV infusion or under the skin. Venetoclax is taken orally at 400 mg every day for all 28 days. This treatment is being evaluated before patients proceed to their planned stem cell transplant. During the study, participants will visit regularly for monitoring and assessments. Researchers will measure the rate of MRD conversion and the degree of MRD decrease over one year. Evaluations include blood tests, bone marrow biopsies, and other clinical assessments to track disease status and treatment effects. The study is sponsored by Memorial Sloan Kettering Cancer Center and aims to follow participants through these key outcome measures.
CONDITIONS
Brief Title
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Research Team
M
Meira Yisraeli Salman, MD
E
Eytan Stein, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
